Don't close this page .. Test is protected .. Answers cannot be changed .. We try now to connect to save and correct your answers.
Connection trial number:
If this message persists for long, please check your internet connection.
This test is monitored
Switching to another webpage or any other program is considered a cheating behavior and your test may be automatically terminated.
Okay
Important Notice
If you moved to the next question, you will not be able to come back to this question again.
Cancel
Move to next question
Final exam لمادة موضوعات مختارة في علم الادوية
Student data
×
Student data
Student name: ***
Student number: ***
Class or section: ***
Test instructions
×
Test instructions
عدد الاسءلة هي 63 سؤال
Page direction
×
Change page direction
Right to left
Left to right
Q1
Score: 0.5
A- category A
B- category B
C- category c
D- category D
E- category x
Q2
Score: 0.5
A- conducting a clinical trial
B- Analyzing the outcome of a clinical trial
C- Givrine permission so clinical trial
D- non the above
Q3
Score: 0.5
A- drug action
B- cell
B- tissue
C- system
Q4
Score: 0.5
Q5
Score: 0.5
A- animal
B- human
C- in vivo
Q6
Score: 0.5
Q7
Score: 0.5
A- Elderly people
B- Infant
C- they are the major consumer of drug
D- include polypharmacy
Q8
Score: 0.5
A- digoxin
B- NSAIDS
C- Atropine- like drugs
Q9
Score: 0.5
Q10
Score: 0.5
Q11
Score: 0.5
A- pharmacodynamic drug- drug interaction
B- pharmacokinetic drug- drug interaction
C- pharmaceutic interaction
Q12
Score: 0.5
Q13
Score: 0.5
A- 5- 10 years
B- 1 month
C- 15- 25 years
D- 9 month to 3 years
Q14
Score: 0.5
صح
خطأ
Q15
Score: 0.5
A- drugs
B- food additives
C- cosmetic
D- pesticide
E- all of the above
Q16
Score: 0.5
A- vaccination
B- blood transfusion
C- transplantation
D- drug therapy
Q17
Score: 0.5
A- pharmaceutic interaction
B- pharmacodynamic interaction
C- pharmacokinetic interaction
Q18
Score: 0.5
A- structural
B- spontaneous
C- antidotal
D- route of exposure
Q19
Score: 0.5
صح
خطأ
Q20
Score: 0.5
A- Easily
B- with difficult
C- poorly
D- non of the above
Q21
Score: 0.5
A- check chemical stability
B- determine major metabolite
C- optimize and scale up synthesis and purification
D- produce GMP batches are required for biological and clinical test
Q22
Score: 0.5
A- sulfonamide
B- Aspirin
C- Mepiridine
D- Benzodiazepine
Q23
Score: 0.5
A- absorption
B- medication compliance
C- reduction in GI motility
D- Elimination
E- A+ D
F- all the above
Q24
Score: 0.5
A- Effect
B- Efficacy
C- Effectiveness
D- BENEFIT
Q25
Score: 0.5
صح
خطأ
Q26
Score: 0.5
صح
خطأ
Q27
Score: 0.5
A- gene
B- protein
C- cell
D- tissue
Q28
Score: 0.5
A- factor including the vascular perfusion
B- By 6 weeks of age
C- such as penicillin
D- are reduced by 50% in premature
Q29
Score: 0.5
A- fetal period
B- organogenesis
C- Blastogenesis
D- non the above
Q30
Score: 0.5
A- spontaneous
B- route of exposure
C- species
D- sex of test animal formulation
Q31
Score: 0.5
A- chemical development
B- safety assessment
C- drug metabolism
D- all the above
Q32
Score: 0.5
Q33
Score: 0.5
A- nasal hypoplasia
B- bone stippling on X- Ray
C- depressed bridge of nose
D- all the above
E- non the above
Q34
Score: 0.5
A- producing hypotension
B- producing hypoglycemia
C- producing hypertension
D- producing hyperglycemia
Q35
Score: 0.5
A- FDA
B- NMR
C- IND
Q36
Score: 0.5
A- Arthritis
B-metabolism
C- peptic ulcer
D- stroke
Q37
Score: 0.5
صح
خطأ
Q38
Score: 0.5
A- result in polar
B- water soluble
C- oxidase
D- conjugation
Q39
Score: 0.5
صح
خطأ
Q40
Score: 0.5
A- digoxin
B- TCAS
C- Atropine like drugs
Q41
Score: 0.5
A- Clark's Rule
B- Youngs Rule
C- creatinine clearance
D- non the above
Q42
Score: 0.5
A- mental retardation
B- Hyperactivity
C- all the above
D- non of the above
Q43
Score: 0.5
A- poly pharmacy
B- multiple disease state
C- increase severity of illness
D- B+ C
E- all the above
Q44
Score: 0.5
A- usually placebo controlled
B- phase IIa is exploratory and phase IIb is confirmatory
C- the opproxinate number of healthy subject is 50- 500
D- gives confirmation of clinical dose and regimen for efficacy
Q45
Score: 0.5
صح
خطأ
Q46
Score: 0.5
A- transplant surgery
B- Apligraf
C- B cell
D- influenza
Q47
Score: 0.5
صح
خطأ
Q48
Score: 0.5
A- In vivo
B- in human
C- in animal
D- in vitro
Q49
Score: 0.5
A- Health
B- disease
C- organization
D- non the above
Q50
Score: 0.5
صح
خطأ
Q51
Score: 0.5
A- urinary retention
B- hyperglycemia
C- heart block
D- GI hemorrhage
Q52
Score: 0.5
A- strength of hypothesis
B- Availibility of target
C- market prediction
D- Toxicology
Q53
Score: 0.5
Q54
Score: 0.5
A- dose
B- Age
C- systemic toxicity
D- Route
Q55
Score: 0.5
A- mental retardation
B- Mutagenesis
C- is seen in up to 25% of the fetuses with first - trimester exposure to coumarins
D- carcinogenesis
Q56
Score: 0.5
صح
خطأ
Q57
Score: 0.5
صح
خطأ
Q58
Score: 0.5
Q59
Score: 0.5
صح
خطأ
Q60
Score: 0.5
A- chemical modification of known molecule
B- biotechnology and cloning
C- random screening for biological activity of large numbers of natural
D- all the above
Q61
Score: 0.5
صح
خطأ
Q62
Score: 0.5
صح
خطأ
Q63
Score: 0.5
صح
خطأ
Q64
Score: 0.5
A- phase -1
B- phase- 2
Q65
Score: 0.5
A- albumin
B- alpha-1 acid glycoproteins
C- T cell
Q66
Score: 0.5
Q67
Score: 0.5
A- Antibodies
B- vaccines
C- enzyme
D- DNA product
Q68
Score: 0.5
A- pregnancy
B- cough
C- diarrhea
D- heart
Q69
Score: 0.5
A- lethal dose to assayed in the same population
B- dose required for sub- lethal toxicity
C- all the above
Q70
Score: 0.5
A- Aspirin
B- sulfonamide
C- chloramphenicol
D- Tetracycline
Q71
Score: 0.5
Q72
Score: 0.5
A- phase I
B- phase II
C- phaseI and II and III and IV
D- phase III
Q73
Score: 0.5
A- pharmacodynamic
B- direct toxicity
C- genotoxicity
D- all the above
Q74
Score: 0.5
A- treatment of pre- existing chronic disorder
B- always use drugs which have been widely used
C- over the counter
D- drugs for medical condition prior to confirmation of pregnancy
Q75
Score: 0.5
صح
خطأ
Q76
Score: 0.5
صح
خطأ
Q77
Score: 0.5
صح
خطأ
Q78
Score: 0.5
صح
خطأ
Q79
Score: 0.5
صح
خطأ
Q80
Score: 0.5
Questions you haven't answered yet:
Are you sure you want to end this test and send your answers?
All copy rights reserved
©
arab-exams.com
2014-2023
Dismiss this alert